Page 1253, column 2, section 4, paragraph 1, lines 4-10: The following sentence, which previously read: ''These data are dervied from a phase I/II study in combination with capecitabine, [13] a phase II trial in patients with metastatic breast cancer (MBC), [15] and a phase III trial in patients with metastatic castration-resistant protein cancer (mCRPC)'' has now been corrected as follows:
''These data are dervied from a phase I/II study in combination with capecitabine, [13] a phase II trial in patients with metastatic breast cancer (MBC), [15] and a phase III trial in patients with metastatic castration-resistant prostate cancer (mCRPC)''.
Page 1256, column 1, section 6, paragraph 3, lines 16-20: The following sentence, which previously read: ''These results offer promising evidence in support of combination therapy with cabazitazel plus capecitabine or other chemotherapeutic agents, but development of this drug has been discontinued for breast cancer'' has now been corrected as follows:
''These results offer promising evidence in support of combination therapy with cabazitazel plus capecitabine or other chemotherapeutic agents.'' Note All online versions of this article have been updated to reflect this correction. Drugs 2011; doi: 10.2165/11596810-000000000-00000 0012-6667/11/0000-0000
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